A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs JNJ 73763989 (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
- 06 Dec 2019 Planned End Date changed from 30 Jan 2020 to 30 Sep 2020.
- 06 Dec 2019 Planned primary completion date changed from 30 Oct 2019 to 30 Jun 2020.
- 08 Nov 2019 Results published in the Arrowhead Pharmaceuticals Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History